Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Visionary Holdings Inc. has signed an Investment Cooperation Agreement with Qingdao Xihai Rongke Enterprise Operation Management Co., Ltd. for a proposed US$20 million strategic investment in Visionary’s Qingdao anti-aging project in Qingdao West Coast New Area, China.
The parties plan to establish a project company to operate the collaboration, including the “GV China Anti-Aging Research Center” with an initial focus on research and translational development in cell therapy and biologics. The project company is also expected to build a “GV Anti-Aging Health Management Center” chain model, initially targeting the Shandong market.
The investor intends to fund at least US$20 million in two phases, with milestone-based payments: 30% upon project company establishment and capital account opening, 40% after research center renovation and equipment installation, and 30% after the first flagship center opens and generates its first month of operating data. A second-phase US$10 million investment is contemplated based on development progress.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026